Folotyn

Author : Reviewer

FOLOTYN (pralatrexate) is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The indication for FOLOTYN is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

FOLOTYN safety information and side effects
FOLOTYN may suppress bone marrow function, manifested by thrombocytopenia, neutropenia, and anemia. Monitor blood counts and omit or modify dose for hematologic toxicities (see Dosage and Administration, section 2.5).

Mucositis may occur. If ≥Grade 2 mucositis is observed, omit or modify dose (see Dosage and Administration, section 2.5). Patients should be instructed to take folic acid and receive vitamin B12 to potentially reduce treatment-related hematological toxicity and mucositis.

FOLOTYNTM can cause fetal harm. Women should avoid becoming pregnant while being treated with FOLOTYNTM and pregnant women should be informed of the potential harm to the fetus.

Use caution and monitor patients when administering FOLOTYNTM to patients with moderate to severe renal function impairment. Elevated liver function test abnormalities may occur and require monitoring. If liver function test abnormalities are ≥Grade 3, omit or modify dose (see Dosage and Administration, section 2.5).

The most common adverse reactions were mucositis (70%), thrombocytopenia (41%), nausea (40%), and fatigue (36%). The most common serious adverse events are pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia.

Leave a Reply

You must be logged in to post a comment.


Copyrighted © 2010 All Drug Reviews | Privacy Policy